Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
12
03
2018
accepted:
02
01
2019
revised:
14
12
2018
pubmed:
6
2
2019
medline:
31
10
2019
entrez:
6
2
2019
Statut:
ppublish
Résumé
Solid malignancies are frequently infiltrated with T cells. The success of adoptive cell transfer (ACT) with expanded tumour-infiltrating lymphocytes (TILs) in melanoma warrants its testing in other cancer types. In this preclinical study, we investigated whether clinical-grade TILs could be manufactured from ovarian cancer (OC) tumour specimens. Thirty-four tumour specimens were obtained from 33 individual patients with OC. TILs were analysed for phenotype, antigen specificity and functionality. Minimally expanded TILs (Young TILs) were successfully established from all patients. Young TILs contained a high frequency of CD3 These findings support the hypothesis that patients with OC can benefit from ACT with TILs and led to the initiation of a pilot clinical trial at our institution . clinicaltrials.gov: NCT02482090.
Sections du résumé
BACKGROUND
Solid malignancies are frequently infiltrated with T cells. The success of adoptive cell transfer (ACT) with expanded tumour-infiltrating lymphocytes (TILs) in melanoma warrants its testing in other cancer types. In this preclinical study, we investigated whether clinical-grade TILs could be manufactured from ovarian cancer (OC) tumour specimens.
METHODS
Thirty-four tumour specimens were obtained from 33 individual patients with OC. TILs were analysed for phenotype, antigen specificity and functionality.
RESULTS
Minimally expanded TILs (Young TILs) were successfully established from all patients. Young TILs contained a high frequency of CD3
CONCLUSION
These findings support the hypothesis that patients with OC can benefit from ACT with TILs and led to the initiation of a pilot clinical trial at our institution .
TRIAL REGISTRATION
clinicaltrials.gov: NCT02482090.
Identifiants
pubmed: 30718808
doi: 10.1038/s41416-019-0384-y
pii: 10.1038/s41416-019-0384-y
pmc: PMC6461863
doi:
Substances chimiques
Interferon-gamma
82115-62-6
Banques de données
ClinicalTrials.gov
['NCT02482090']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
424-434Commentaires et corrections
Type : ErratumIn
Références
Clin Cancer Res. 2014 Jan 15;20(2):331-43
pubmed: 24218514
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Mol Cell Proteomics. 2018 Mar;17(3):533-548
pubmed: 29242379
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
J Immunother. 2011 Mar;34(2):212-20
pubmed: 21304398
Anticancer Res. 2009 Jan;29(1):145-54
pubmed: 19331144
Clin Cancer Res. 2010 May 1;16(9):2646-55
pubmed: 20406835
Curr Opin Immunol. 2013 Apr;25(2):284-90
pubmed: 23566921
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
J Immunother. 2012 Jun;35(5):400-8
pubmed: 22576345
Br J Cancer. 2015 Apr 28;112(9):1510-8
pubmed: 25867267
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Cancer Immunol Immunother. 2018 Oct;67(10):1519-1531
pubmed: 30039427
Cancer Res. 2009 Nov 1;69(21):8412-9
pubmed: 19843860
Cancer Res. 1999 Jul 1;59(13):3157-65
pubmed: 10397259
Nat Med. 2006 Feb;12(2):246-51
pubmed: 16462803
Curr Opin Immunol. 2016 Aug;41:9-17
pubmed: 27155075
Clin Cancer Res. 2017 Feb 15;23(4):925-934
pubmed: 27601594
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Res. 2015 Sep 15;75(18):3747-59
pubmed: 26183926
Scand J Immunol. 2012 Feb;75(2):157-67
pubmed: 21955245
Cytotherapy. 2014 Aug;16(8):1117-20
pubmed: 24831841
Cancer. 2009 Jul 1;115(13):2891-902
pubmed: 19472394
J Immunol Methods. 2014 Mar;405:192-8
pubmed: 24486140
J Urol. 2012 Dec;188(6):2148-9
pubmed: 23141220
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
PLoS One. 2016 May 18;11(5):e0155189
pubmed: 27192170
Cancer Immunol Res. 2018 Feb;6(2):222-235
pubmed: 29301752
Clin Cancer Res. 2014 Mar 1;20(5):1125-34
pubmed: 24323902
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15
pubmed: 27141063
Cytotherapy. 2011 Aug;13(7):822-34
pubmed: 21428850
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Eur J Immunol. 2016 Jun;46(6):1351-60
pubmed: 27005018
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Clin Cancer Res. 2016 Aug 1;22(15):3734-45
pubmed: 27006492